FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016020844> ?p ?o ?g. }

• W2016020844 endingPage "384" @default.
• W2016020844 startingPage "376" @default.
• W2016020844 abstract "Invariant natural killer T cells recognize glycolipid antigens such as α-galactosylceramide presented by CD1d. In preclinical models of B-cell malignancies, α-galactosylceramide is an adjuvant to tumor vaccination, enhancing tumor-specific T-cell responses and prolonging survival. However, numerical and functional invariant natural killer T-cell defects exist in patients with some cancers. Our aim was to assess this axis in patients with chronic lymphocytic leukemia. The numbers of circulating invariant natural killer T cells and the expression of CD1d on antigen-presenting cells were evaluated in patients with chronic lymphocytic leukemia and age-matched controls. Cytokine profile and in vitro proliferative capacity were determined. Patient- and control-derived invariant natural killer T-cell lines were generated and characterized, and allogeneic and autologous responses to α-galactosylce-ramide-treated leukemia cells were assessed. Absolute numbers and phenotype of invariant natural killer T cells were normal in patients with untreated chronic lymphocytic leukemia, and cytokine profile and proliferative capacity were intact. Chemotherapy-treated patients had reduced numbers of invariant natural killer T cells and myeloid dendritic cells, but α-galactosylceramide-induced proliferation was preserved. Invariant natural killer T-cell lines from patients lysed CD1d-expressing targets. Irradiated α-galactosylceramide-treated leukemic cells elicited allogeneic and autologous invariant natural killer T-cell proliferation, and α-galactosylceramide treatment led to increased proliferation of conventional T cells in response to tumor. In conclusion, the invariant natural killer T-cell and CD1d axis is fundamentally intact in patients with early-stage chronic lymphocytic leukemia and, despite reduced circulating numbers, function is retained in fludarabine-treated patients. Immunotherapies exploiting the adjuvant effect of α-galactosylceramide may be feasible." @default.
• W2016020844 created "2016-06-24" @default.
• W2016020844 creator A5001620682 @default.
• W2016020844 creator A5003749792 @default.
• W2016020844 creator A5013523216 @default.
• W2016020844 creator A5014939316 @default.
• W2016020844 creator A5044717633 @default.
• W2016020844 date "2012-10-12" @default.
• W2016020844 modified "2023-10-18" @default.
• W2016020844 title "Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy" @default.
• W2016020844 cites W1513668367 @default.
• W2016020844 cites W1538328956 @default.
• W2016020844 cites W154103547 @default.
• W2016020844 cites W1563051276 @default.
• W2016020844 cites W1607981534 @default.
• W2016020844 cites W1678468169 @default.
• W2016020844 cites W1837611478 @default.
• W2016020844 cites W1964742152 @default.
• W2016020844 cites W1966676810 @default.
• W2016020844 cites W1972188277 @default.
• W2016020844 cites W1972884449 @default.
• W2016020844 cites W1972892653 @default.
• W2016020844 cites W1977677274 @default.
• W2016020844 cites W1984847897 @default.
• W2016020844 cites W1984890218 @default.
• W2016020844 cites W1984947358 @default.
• W2016020844 cites W1989322067 @default.
• W2016020844 cites W1992511428 @default.
• W2016020844 cites W1994747498 @default.
• W2016020844 cites W1999504973 @default.
• W2016020844 cites W2008785727 @default.
• W2016020844 cites W2021532646 @default.
• W2016020844 cites W2024972563 @default.
• W2016020844 cites W2027769480 @default.
• W2016020844 cites W2037351868 @default.
• W2016020844 cites W2042155937 @default.
• W2016020844 cites W2042629107 @default.
• W2016020844 cites W2050699423 @default.
• W2016020844 cites W2059250009 @default.
• W2016020844 cites W2065202184 @default.
• W2016020844 cites W2072256836 @default.
• W2016020844 cites W2078873025 @default.
• W2016020844 cites W2086637735 @default.
• W2016020844 cites W2087379854 @default.
• W2016020844 cites W2094147411 @default.
• W2016020844 cites W2100318750 @default.
• W2016020844 cites W2106104133 @default.
• W2016020844 cites W2114307517 @default.
• W2016020844 cites W2116120238 @default.
• W2016020844 cites W2116556475 @default.
• W2016020844 cites W2122582242 @default.
• W2016020844 cites W2122792339 @default.
• W2016020844 cites W2130011407 @default.
• W2016020844 cites W2131660203 @default.
• W2016020844 cites W2140173432 @default.
• W2016020844 cites W2150998778 @default.
• W2016020844 cites W2158313081 @default.
• W2016020844 cites W2161307276 @default.
• W2016020844 cites W2165107917 @default.
• W2016020844 cites W2169320123 @default.
• W2016020844 cites W2170417753 @default.
• W2016020844 cites W2395914225 @default.
• W2016020844 cites W2582398023 @default.
• W2016020844 doi "https://doi.org/10.3324/haematol.2012.072835" @default.
• W2016020844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3659950" @default.
• W2016020844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23065503" @default.
• W2016020844 hasPublicationYear "2012" @default.
• W2016020844 type Work @default.
• W2016020844 sameAs 2016020844 @default.
• W2016020844 citedByCount "33" @default.
• W2016020844 countsByYear W20160208442013 @default.
• W2016020844 countsByYear W20160208442014 @default.
• W2016020844 countsByYear W20160208442015 @default.
• W2016020844 countsByYear W20160208442016 @default.
• W2016020844 countsByYear W20160208442017 @default.
• W2016020844 countsByYear W20160208442018 @default.
• W2016020844 countsByYear W20160208442019 @default.
• W2016020844 countsByYear W20160208442020 @default.
• W2016020844 countsByYear W20160208442021 @default.
• W2016020844 countsByYear W20160208442022 @default.
• W2016020844 countsByYear W20160208442023 @default.
• W2016020844 crossrefType "journal-article" @default.
• W2016020844 hasAuthorship W2016020844A5001620682 @default.
• W2016020844 hasAuthorship W2016020844A5003749792 @default.
• W2016020844 hasAuthorship W2016020844A5013523216 @default.
• W2016020844 hasAuthorship W2016020844A5014939316 @default.
• W2016020844 hasAuthorship W2016020844A5044717633 @default.
• W2016020844 hasBestOaLocation W20160208441 @default.
• W2016020844 hasConcept C139563560 @default.
• W2016020844 hasConcept C147483822 @default.
• W2016020844 hasConcept C154317977 @default.
• W2016020844 hasConcept C202751555 @default.
• W2016020844 hasConcept C203014093 @default.
• W2016020844 hasConcept C2776090121 @default.
• W2016020844 hasConcept C2777701055 @default.
• W2016020844 hasConcept C2777938653 @default.
• W2016020844 hasConcept C2778102761 @default.
• W2016020844 hasConcept C2778461978 @default.

• next